oxybutynin has been researched along with Low Back Ache in 10 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study examines the efficacy of the buprenorphine transdermal system (BTDS) for reducing the interference of pain on physical and emotional functioning associated with chronic low back pain (CLBP)." | 9.20 | Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain. ( Lynch, SY; Miller, K; Munera, C; Pergolizzi, JV; Raffa, R; Ripa, SR; Wen, W; Yarlas, A, 2015) |
| "To evaluate the impact of 12 weeks of treatment with Butrans® (buprenorphine) transdermal system (BTDS) on the health-related quality of life (HRQoL) for patients with chronic low back pain (CLBP), and the maintenance of effects over 52 weeks." | 9.17 | Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain. ( Brennan, MJ; Dain, B; Lynch, SY; Miller, K; Ripa, SR; Wen, W; Yarlas, A, 2013) |
| "In this enriched design study, 1,160 opioid-experienced patients with chronic, moderate to severe low back pain entered an open-label run-in period; 660 demonstrated analgesic benefit from and tolerability to buprenorphine transdermal system 20 mcg/hour (BTDS 20) treatment and were randomized to receive either BTDS 20, BTDS 5 mcg/hour (BTDS 5), or the active control (immediate release oxycodone 40-mg/day) during an 84-day double-blind phase." | 9.15 | Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study. ( Hale, M; Landau, C; Munera, C; Ripa, S; Steiner, D, 2011) |
| "Local anesthetics, such as the 5% transdermal lidocaine patch (5LP), have been frequently used in the treatment of musculoskeletal pain, especially chronic low back pain (CLBP)." | 9.05 | The Efficacy, Effectiveness and Safety of 5% Transdermal Lidocaine Patch for Chronic Low Back Pain: A Narrative Review. ( Felix, ER; Klass, S; Santana, JA, 2020) |
| "A number of studies have been published proposing various approaches to the treatment of neuropathic pain; however, to our knowledge, no attempts have been made to compare gabapentin and fentanyl in patients with lumbar radiculopathy." | 5.30 | Gabapentin versus Transdermal Fentanyl Matrix for the Alleviation of Chronic Neuropathic Pain of Radicular Origin: A Randomized Blind Multicentered Parallel-Group Noninferiority Trial. ( Hwang, CJ; Kim, JH; Lee, JH; Min, SH; Park, KW; Seo, HY; Song, KS, 2019) |
| "This study examines the efficacy of the buprenorphine transdermal system (BTDS) for reducing the interference of pain on physical and emotional functioning associated with chronic low back pain (CLBP)." | 5.20 | Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain. ( Lynch, SY; Miller, K; Munera, C; Pergolizzi, JV; Raffa, R; Ripa, SR; Wen, W; Yarlas, A, 2015) |
| "To evaluate the impact of 12 weeks of treatment with Butrans® (buprenorphine) transdermal system (BTDS) on the health-related quality of life (HRQoL) for patients with chronic low back pain (CLBP), and the maintenance of effects over 52 weeks." | 5.17 | Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain. ( Brennan, MJ; Dain, B; Lynch, SY; Miller, K; Ripa, SR; Wen, W; Yarlas, A, 2013) |
| "In this enriched design study, 1,160 opioid-experienced patients with chronic, moderate to severe low back pain entered an open-label run-in period; 660 demonstrated analgesic benefit from and tolerability to buprenorphine transdermal system 20 mcg/hour (BTDS 20) treatment and were randomized to receive either BTDS 20, BTDS 5 mcg/hour (BTDS 5), or the active control (immediate release oxycodone 40-mg/day) during an 84-day double-blind phase." | 5.15 | Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study. ( Hale, M; Landau, C; Munera, C; Ripa, S; Steiner, D, 2011) |
| "Local anesthetics, such as the 5% transdermal lidocaine patch (5LP), have been frequently used in the treatment of musculoskeletal pain, especially chronic low back pain (CLBP)." | 5.05 | The Efficacy, Effectiveness and Safety of 5% Transdermal Lidocaine Patch for Chronic Low Back Pain: A Narrative Review. ( Felix, ER; Klass, S; Santana, JA, 2020) |
| " Herein we report a patient with opioid-induced delirium associated with the administration of buprenorphine patches that was well below the indicated therapeutic range limit." | 3.79 | A case of topical opioid-induced delirium mistaken as behavioural and psychological symptoms of dementia in demented state. ( Ito, G; Kanemoto, K, 2013) |
| " We analyzed data from 5 open-label clinical trials of lidocaine patch 5% in osteoarthritis knee pain and chronic low back pain that were 2 to 12 weeks in duration." | 3.77 | Treatment satisfaction in osteoarthritis and chronic low back pain: the role of pain, physical and emotional functioning, sleep, and adverse events. ( Dworkin, RH; Galer, BS; Gammaitoni, AR; Gould, E; Jensen, MP; Jones, BA; Xiang, Q, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Santana, JA | 1 |
| Klass, S | 1 |
| Felix, ER | 1 |
| Uğurlu, M | 1 |
| Aksekili, MAE | 1 |
| Alkan, BM | 1 |
| Kara, H | 1 |
| Çağlar, C | 1 |
| Tanaka, S | 1 |
| Kanagawa, T | 1 |
| Momma, K | 1 |
| Hori, S | 1 |
| Satoh, H | 1 |
| Nagamatsu, T | 1 |
| Fujii, T | 1 |
| Kimura, T | 1 |
| Sawada, Y | 1 |
| Hwang, CJ | 1 |
| Lee, JH | 1 |
| Kim, JH | 1 |
| Min, SH | 1 |
| Park, KW | 1 |
| Seo, HY | 1 |
| Song, KS | 1 |
| Ito, G | 1 |
| Kanemoto, K | 1 |
| Yarlas, A | 2 |
| Miller, K | 2 |
| Wen, W | 2 |
| Lynch, SY | 2 |
| Munera, C | 2 |
| Pergolizzi, JV | 1 |
| Raffa, R | 1 |
| Ripa, SR | 2 |
| Sáez-González, E | 1 |
| Díaz-Jaime, FC | 1 |
| García-Morales, N | 1 |
| Herreras-López, J | 1 |
| Ortiz, V | 1 |
| Ortuño, J | 1 |
| Garrigues, V | 1 |
| Dworkin, RH | 1 |
| Jensen, MP | 1 |
| Gould, E | 1 |
| Jones, BA | 1 |
| Xiang, Q | 1 |
| Galer, BS | 1 |
| Gammaitoni, AR | 1 |
| Steiner, D | 1 |
| Hale, M | 1 |
| Ripa, S | 1 |
| Landau, C | 1 |
| Dain, B | 1 |
| Brennan, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Gabapentin Versus Transdermal Fentanyl Matrix (TDF) for Chronic Neuropathic Pain (of Radicular Origin): A Multicenter Randomized, Parallel Group, Rater Blinded, Non-inferiority Trial[NCT01127100] | Phase 4 | 108 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| A Multicenter, Randomized, Double-blind, Active Comparator Study to Determine the Efficacy and Safety of BTDS 20 or Oxycodone Immediate-release Versus BTDS 5 in Subjects With Moderate to Severe Low Back Pain[NCT00313014] | Phase 3 | 660 participants (Actual) | Interventional | 2004-02-29 | Terminated (stopped due to Terminated early due to administrative reasons unrelated to efficacy or safety.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The mean daily number of tablets of supplemental analgesic medications used during the double-blind phase (NCT00313014)
Timeframe: Double-blind phase (84 days)
| Intervention | tablets (Mean) |
|---|---|
| Double-blind BTDS 5 | 3.8 |
| Double-blind BTDS 20 | 3.3 |
| Double-blind Oxycodone Immediate-Release | 3.5 |
"Subjects were evaluated during the double-blind phase for average pain over the last 24 hours prior to the study visits. Pain scale is 11 points (0 = no pain to 10 = pain as bad as you can imagine)" (NCT00313014)
Timeframe: Last 24 hours score at weeks 4, 8, 12 of the double-blind phase
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Screening | Prerandomization | Week 4 | Week 8 | Week 12 | |
| Double-blind BTDS 20 | 6.46 | 2.91 | 3.40 | 3.35 | 3.35 |
| Double-blind BTDS 5 | 6.36 | 2.84 | 3.79 | 3.83 | 4.02 |
| Double-blind Oxycodone Immediate-Release | 6.46 | 2.74 | 3.14 | 3.24 | 3.26 |
"The ODI (version 2) is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire that is usually completed in less than 5 minutes.~The ODI consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0 = good to 5 = worse). (Note: A higher score represents greater disability.)" (NCT00313014)
Timeframe: Weeks 4, 8, 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Week 4 | Week 8 | Week 12 | |
| Double-blind BTDS 20 | 33.04 | 34.27 | 33.06 |
| Double-blind BTDS 5 | 34.80 | 35.69 | 36.30 |
| Double-blind Oxycodone Immediate-Release | 30.79 | 31.64 | 32.96 |
"The MOS-Sleep Scale consists of 12 individual items: (4 sleep disturbance, 2 sleep adequacy, 1 quantity/ optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath).~Question 1 is scored on a scale of 1 to 5 and Questions 3 to 12 are scored on a scale of 1 to 6. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7 and 8, and ranges from 0 to 100, where higher scores indicate greater sleep disturbance." (NCT00313014)
Timeframe: Weeks 4, 8, 12 of the double-blind phase
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Week 4 | Week 8 | Week 12 | |
| Double-blind BTDS 20 | 34.65 | 35.69 | 33.65 |
| Double-blind BTDS 5 | 40.67 | 42.28 | 40.85 |
| Double-blind Oxycodone Immediate-Release | 38.10 | 39.17 | 41.60 |
1 review available for oxybutynin and Low Back Ache
| Article | Year |
|---|---|
The Efficacy, Effectiveness and Safety of 5% Transdermal Lidocaine Patch for Chronic Low Back Pain: A Narrative Review.
Topics: Anesthetics, Local; Chronic Pain; Humans; Lidocaine; Low Back Pain; Randomized Controlled Trials as | 2020 |
5 trials available for oxybutynin and Low Back Ache
| Article | Year |
|---|---|
Effects of Artcure Diffusional Patch application on pain and functional status in lumbar disc herniation patients: a prospective randomized controlled study.
Topics: Adolescent; Adult; Analgesics; Disability Evaluation; Female; Humans; Intervertebral Disc Degenerati | 2017 |
Gabapentin versus Transdermal Fentanyl Matrix for the Alleviation of Chronic Neuropathic Pain of Radicular Origin: A Randomized Blind Multicentered Parallel-Group Noninferiority Trial.
Topics: Administration, Cutaneous; Adult; Analgesics; Double-Blind Method; Female; Fentanyl; Gabapentin; Hum | 2019 |
Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Buprenorphine; Chronic Pain; Double-Blind Meth | 2015 |
Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study.
Topics: Administration, Cutaneous; Analgesics, Opioid; Buprenorphine; Chronic Pain; Double-Blind Method; Fem | 2011 |
Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Buprenorphine; Chronic Pain; Dose-Response Rel | 2013 |
4 other studies available for oxybutynin and Low Back Ache
| Article | Year |
|---|---|
Prediction of sustained fetal toxicity induced by ketoprofen based on PK/PD analysis using human placental perfusion and rat toxicity data.
Topics: Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Biomarkers, Pharmacological; Co | 2017 |
A case of topical opioid-induced delirium mistaken as behavioural and psychological symptoms of dementia in demented state.
Topics: Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Confusion; Delirium; Dementia; Female; Halluci | 2013 |
Opioid-induced functional esophagogastric junction obstruction.
Topics: Analgesics, Opioid; Buprenorphine; Deglutition Disorders; Esophageal Spasm, Diffuse; Esophageal Sphi | 2017 |
Treatment satisfaction in osteoarthritis and chronic low back pain: the role of pain, physical and emotional functioning, sleep, and adverse events.
Topics: Anesthetics, Local; Chronic Disease; Clinical Trials as Topic; Female; Humans; Lidocaine; Low Back P | 2011 |